JP2024056687A5 - - Google Patents

Download PDF

Info

Publication number
JP2024056687A5
JP2024056687A5 JP2024003062A JP2024003062A JP2024056687A5 JP 2024056687 A5 JP2024056687 A5 JP 2024056687A5 JP 2024003062 A JP2024003062 A JP 2024003062A JP 2024003062 A JP2024003062 A JP 2024003062A JP 2024056687 A5 JP2024056687 A5 JP 2024056687A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antigen
binding site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2024003062A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024056687A (ja
Filing date
Publication date
Priority claimed from JP2020556869A external-priority patent/JP7475283B2/ja
Application filed filed Critical
Publication of JP2024056687A publication Critical patent/JP2024056687A/ja
Publication of JP2024056687A5 publication Critical patent/JP2024056687A5/ja
Priority to JP2025244101A priority Critical patent/JP2026062683A/ja
Withdrawn legal-status Critical Current

Links

JP2024003062A 2018-04-16 2024-01-12 キレート化された放射性核種に対する抗体 Withdrawn JP2024056687A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025244101A JP2026062683A (ja) 2018-04-16 2025-12-10 キレート化された放射性核種に対する抗体

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862658468P 2018-04-16 2018-04-16
US62/658,468 2018-04-16
JP2020556869A JP7475283B2 (ja) 2018-04-16 2019-04-16 キレート化された放射性核種に対する抗体
PCT/EP2019/059856 WO2019201959A1 (en) 2018-04-16 2019-04-16 Antibodies for chelated radionuclides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020556869A Division JP7475283B2 (ja) 2018-04-16 2019-04-16 キレート化された放射性核種に対する抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025244101A Division JP2026062683A (ja) 2018-04-16 2025-12-10 キレート化された放射性核種に対する抗体

Publications (2)

Publication Number Publication Date
JP2024056687A JP2024056687A (ja) 2024-04-23
JP2024056687A5 true JP2024056687A5 (https=) 2024-09-06

Family

ID=66476592

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020556869A Active JP7475283B2 (ja) 2018-04-16 2019-04-16 キレート化された放射性核種に対する抗体
JP2024003062A Withdrawn JP2024056687A (ja) 2018-04-16 2024-01-12 キレート化された放射性核種に対する抗体
JP2025244101A Pending JP2026062683A (ja) 2018-04-16 2025-12-10 キレート化された放射性核種に対する抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020556869A Active JP7475283B2 (ja) 2018-04-16 2019-04-16 キレート化された放射性核種に対する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025244101A Pending JP2026062683A (ja) 2018-04-16 2025-12-10 キレート化された放射性核種に対する抗体

Country Status (31)

Country Link
US (2) US20220389116A1 (https=)
EP (2) EP3781200B1 (https=)
JP (3) JP7475283B2 (https=)
KR (1) KR102884852B1 (https=)
CN (1) CN112261952A (https=)
AR (1) AR115053A1 (https=)
AU (1) AU2019254537B2 (https=)
BR (1) BR112020021061A2 (https=)
CA (1) CA3096338A1 (https=)
CL (1) CL2020002680A1 (https=)
CR (1) CR20200548A (https=)
DK (1) DK3781200T3 (https=)
ES (1) ES2985352T3 (https=)
FI (1) FI3781200T3 (https=)
HR (1) HRP20241013T1 (https=)
HU (1) HUE067622T2 (https=)
IL (1) IL277575B2 (https=)
LT (1) LT3781200T (https=)
MA (1) MA52545B1 (https=)
MX (1) MX2020010954A (https=)
MY (1) MY207044A (https=)
PE (1) PE20210442A1 (https=)
PL (1) PL3781200T3 (https=)
PT (1) PT3781200T (https=)
RS (1) RS65753B1 (https=)
SG (1) SG11202010066TA (https=)
SI (1) SI3781200T1 (https=)
TW (1) TWI874314B (https=)
UA (1) UA130541C2 (https=)
WO (1) WO2019201959A1 (https=)
ZA (1) ZA202006121B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
AR119382A1 (es) * 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
CR20230076A (es) * 2020-07-10 2023-03-13 Hoffmann La Roche Anticuerpos que se unen a células cancerosas y dirigen radionucleótidos a dichas células
JP2024504931A (ja) 2021-01-12 2024-02-02 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト がん細胞に結合し、放射性核種を前記細胞に標的化するスプリット抗体
CA3204291A1 (en) 2021-01-13 2022-07-21 F. Hoffmann-La Roche Ag Combination therapy
CN116744981A (zh) * 2021-01-13 2023-09-12 豪夫迈·罗氏有限公司 组合疗法
JP2024546810A (ja) 2021-12-15 2024-12-26 ワイ-マブス セラピューティクス, インコーポレイテッド 多量体化が低減されているscFv及び抗体
WO2024099526A1 (en) 2022-11-08 2024-05-16 Y-Mabs Therapeutics, Inc. Bispecific antibody compounds
WO2025176614A1 (en) 2024-02-20 2025-08-28 F. Hoffmann-La Roche Ag Novel pre-targeting antibodies and uses thereof
WO2026041568A1 (en) 2024-08-20 2026-02-26 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and dotam
WO2026082710A1 (en) 2024-10-16 2026-04-23 F. Hoffmann-La Roche Ag Small molecule-inducible recombinant receptors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201608192SA (en) * 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
ES2809598T3 (es) 2014-12-23 2021-03-04 Inst Nat Sante Rech Med Composiciones farmacéuticas para el tratamiento de superinfecciones bacterianas post-influenza
EP3253799B1 (en) * 2015-02-05 2020-12-02 Molecular Templates, Inc. Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
CN107847584B (zh) * 2015-02-09 2022-01-25 纪念斯隆凯特琳癌症中心 具有人a33抗原和dota金属复合物亲和力的多特异性抗体及其用途
PE20180484A1 (es) * 2015-10-02 2018-03-07 Hoffmann La Roche Moleculas biespecificas de union a antigeno activadoras de celulas t
EP3243836A1 (en) * 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
CN112638416A (zh) 2018-04-16 2021-04-09 奥兰诺医药公司 针对螯合的放射性核素的抗体和清除剂

Similar Documents

Publication Publication Date Title
JP2024056687A5 (https=)
HRP20241013T1 (hr) Protutijela za kelatirane radionuklide
JP2021520832A5 (https=)
JP2023134618A5 (https=)
JP2021534096A5 (https=)
JP2021501162A5 (https=)
HRP20201928T1 (hr) Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1
JP2023538945A5 (https=)
JP2021533159A5 (https=)
JP2018510636A5 (https=)
JP2021514973A5 (https=)
RU2008149918A (ru) Антитела к nkg2a и их применения
RU2016145277A (ru) Антитело против igf-1r и его применение в качестве адресующего переносчика для лечения рака
RU2015115956A (ru) Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
JP2016503067A5 (https=)
JP2024086870A5 (https=)
JP2016505546A5 (https=)
JP2021522347A5 (https=)
JP2016527225A5 (https=)
JP2018093875A5 (https=)
JP2023549555A5 (https=)
JP2023548529A5 (https=)
JP2022540610A5 (https=)
JP2023509214A5 (https=)
JP2022521305A (ja) 抗pd-l1抗体及びその使用